1. Home
  2. NTRA vs IX Comparison

NTRA vs IX Comparison

Compare NTRA & IX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • IX
  • Stock Information
  • Founded
  • NTRA 2003
  • IX 1950
  • Country
  • NTRA United States
  • IX Japan
  • Employees
  • NTRA N/A
  • IX N/A
  • Industry
  • NTRA Medical Specialities
  • IX Diversified Financial Services
  • Sector
  • NTRA Health Care
  • IX Finance
  • Exchange
  • NTRA Nasdaq
  • IX Nasdaq
  • Market Cap
  • NTRA 20.9B
  • IX 22.8B
  • IPO Year
  • NTRA 2015
  • IX 1970
  • Fundamental
  • Price
  • NTRA $151.95
  • IX $20.12
  • Analyst Decision
  • NTRA Strong Buy
  • IX
  • Analyst Count
  • NTRA 17
  • IX 0
  • Target Price
  • NTRA $178.41
  • IX N/A
  • AVG Volume (30 Days)
  • NTRA 1.1M
  • IX 352.6K
  • Earning Date
  • NTRA 05-08-2025
  • IX 05-16-2025
  • Dividend Yield
  • NTRA N/A
  • IX 3.24%
  • EPS Growth
  • NTRA N/A
  • IX 35.99
  • EPS
  • NTRA N/A
  • IX 2.21
  • Revenue
  • NTRA $1,831,000,000.00
  • IX $18,605,069,536.00
  • Revenue This Year
  • NTRA $15.45
  • IX $3.95
  • Revenue Next Year
  • NTRA $18.43
  • IX $6.12
  • P/E Ratio
  • NTRA N/A
  • IX $9.02
  • Revenue Growth
  • NTRA 51.50
  • IX 8.06
  • 52 Week Low
  • NTRA $92.14
  • IX $17.75
  • 52 Week High
  • NTRA $183.00
  • IX $25.17
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 49.96
  • IX 51.18
  • Support Level
  • NTRA $153.40
  • IX $19.92
  • Resistance Level
  • NTRA $159.15
  • IX $20.26
  • Average True Range (ATR)
  • NTRA 6.36
  • IX 0.24
  • MACD
  • NTRA 0.65
  • IX 0.06
  • Stochastic Oscillator
  • NTRA 39.44
  • IX 59.09

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About IX Orix Corp Ads

ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.

Share on Social Networks: